MedPath

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Public
Established
2005-01-01
Employees
184
Market Cap
-
Website
http://www.syndax.com

Clinical Trials

17

Active:13
Completed:1

Trial Phases

2 Phases

Phase 1:15
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials

Phase 1
15 (93.8%)
Phase 2
1 (6.3%)
No trials found

News

Syndax's Revumenib Shows Positive Phase II Results in AML

Syndax Pharmaceuticals announced positive top-line results from the pivotal Phase II portion of the Augment-101 study, evaluating revumenib in acute myeloid leukemia (AML).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.